Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1977 Jul 9;117(1):33–36.

Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.

P B McCulloch, P B Dent, M Blajchman, W M Muirhead, R A Price
PMCID: PMC1879633  PMID: 861909

Abstract

Twenty-nine patients referred consecutively to a cancer clinic because of recurrent metastatic malignant melanoma were given 5 mg of Connaught Laboratories bacillus Calmette-Guérin (BCG) by multiple cutaneous puncture at weekly and later at monthly intervals. Eight were also treated with autologous tumour vaccine and three with intralesional BCG. This group was compared with a retrospective control group of 54 patients treated with surgery and radiotherapy alone after recurrence. Prognostic features such as site of primary and of first metastasis, disease-free interval, age and sex were similar in the two groups. However, the median survival from the time of first recurrence was 12 months in the control group but 21 months in the BCG-treated group. The major improvement was in patients with disease limited to the regional lymph nodes: the median survival was 16 months in the control group but over 32 months in the BCG-treated group. Autologous tumour vaccine appeared to have no effect on survival. Serial testing of immunocompetence did not offer any prognostic advantage, although the results of some tests correleated well with extent of disease.

Full text

PDF
33

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker M. A., Taub R. N. Immunotherapy of human cancer. Prog Allergy. 1973;17:227–299. doi: 10.1159/000313296. [DOI] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer. N Engl J Med. 1974 Jun 27;290(26):1458–1469. doi: 10.1056/NEJM197406272902605. [DOI] [PubMed] [Google Scholar]
  3. Cortes E. P., Holland J. F., Wang J. J., Sinks L. F., Blom J., Senn H., Bank A., Glidewell O. Amputation and adriamycin in primary osteosarcoma. N Engl J Med. 1974 Nov 7;291(19):998–1000. doi: 10.1056/NEJM197411072911903. [DOI] [PubMed] [Google Scholar]
  4. Cowan D. H., Bergsagel D. E. Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). Cancer Chemother Rep. 1971 Apr;55(2):175–181. [PubMed] [Google Scholar]
  5. Eilber F. R., Morton D. L., Holmes E. C., Sparks F. C., Ramming K. P. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med. 1976 Jan 29;294(5):237–240. doi: 10.1056/NEJM197601292940501. [DOI] [PubMed] [Google Scholar]
  6. Einhorn L. H., Burgess M. A., Vallejos C., Bodey G. P., Sr, Gutterman J., Mavligit G., Hersh E. M., Luce J. K., Frei E., 3rd, Freireich E. J. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res. 1974 Aug;34(8):1995–2004. [PubMed] [Google Scholar]
  7. Fisher B., Carbone P., Economou S. G., Frelick R., Glass A., Lerner H., Redmond C., Zelen M., Band P., Katrych D. L. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975 Jan 16;292(3):117–122. doi: 10.1056/NEJM197501162920301. [DOI] [PubMed] [Google Scholar]
  8. Gutterman J. U., Hersh E. M., Rodriguez V., McCredie K. B., Mavligit G., Reed R., Burgess M. A., Smith T., Gehan E., Bodey G. P., Sr Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. Lancet. 1974 Dec 14;2(7894):1405–1409. doi: 10.1016/s0140-6736(74)90070-1. [DOI] [PubMed] [Google Scholar]
  9. Gutterman J. U., Mavligit G., McBride C., Frei E., 3rd, Freireich E. J., Hersh E. M. Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet. 1973 Jun 2;1(7814):1208–1212. doi: 10.1016/s0140-6736(73)90526-6. [DOI] [PubMed] [Google Scholar]
  10. Lui V. K., Karpuchas J., Dent P. B., McCulloch P. B., Blajchman M. A. Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy. Br J Cancer. 1975 Sep;32(3):323–330. doi: 10.1038/bjc.1975.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mackie R. M., Carfrae D. C., Cochran A. J. Assessment of prognosis in patients with malignant melanoma. Lancet. 1972 Sep 2;2(7775):455–456. doi: 10.1016/s0140-6736(72)91854-5. [DOI] [PubMed] [Google Scholar]
  12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  13. McKneally M. F., Maver C., Kausel H. W. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet. 1976 Feb 21;1(7956):377–379. doi: 10.1016/s0140-6736(76)90212-9. [DOI] [PubMed] [Google Scholar]
  14. Morton D. L., Eilber F. R., Holmes E. C., Hunt J. S., Ketcham A. S., Silverstein M. J., Sparks F. C. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974 Oct;180(4):635–643. doi: 10.1097/00000658-197410000-00029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pinsky C. M., Hirshaut Y., Wanebo H. J., Fortner J. G., Miké V., Schottenfeld D., Oettgen H. F. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma. Ann N Y Acad Sci. 1976;277(00):187–194. doi: 10.1111/j.1749-6632.1976.tb41697.x. [DOI] [PubMed] [Google Scholar]
  16. Vogler W. R., Chan Y. K. Prolonging remission in myeloblastic leukemia by tice-strain bacillus Calmette-Guérin. Lancet. 1974 Jul 20;2(7873):128–131. doi: 10.1016/s0140-6736(74)91556-6. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES